Technology Opportunities

Anti-Allergy Inhaled and Intranasal Microparticles

Highlights

• Prevention of IgE-mediated allergic reaction by blocking and clearing pollen allergens with oxidized cellulose via its polysaccharide binding domain.
• Mode of administration: inhalation, intranasal, ocular, topical and mucosal.
• Oxidized cellulose has a long safety track record as an invasive medical device.
• A commercial source of GMP manufactured oxidized cellulose has been selected.
• Easy 510(k) regulatory pathway for certain indications.

Our Innovation

• Oxidized cellulose, effectively prevents allergies, asthma and hay fever.
• This is a biodegradable and biocompatible product that has exhibited a high efficiency for binding a broad-spectrum of allergens (pollen, mites, egg and cat dander).
• The low solubility level enables it to be cleared by the mucocilliary system from the airways to the gastro-intestinal track. In addition, the oxidised cellulose, bind the allergens and prevents epithelium barrier penetration thus prevents allergic reaction..
• The half life of oxidized cellulose is 14 days in the lungs and 55 days in the body.
• Mouse and Rat models (in vivo and in vitro) have established oxidized cellulose powder inhalation as an effective treatment in the reduction of allergic inflammation in the lungs.
• In-vitro assays have been developed to demonstrate mode of action and

The opportunity

• 5 to 15% of the population in industrialized world have asthma. The prevalence and morbidity of asthmas has been on the rise, despite standard (steroids) and new treatments.
• Asthma is the third leading cause of hospitalization among persons under the age of 18.
• Allergy related symptoms such as atopic dermatitis and hay fever affect huge populations.

Development Milestones

• The project is presently seeking to raise additional $2M to complete preclinical and toxicology studies and to initiate clinical trials.